Application for registration of new lung cancer drug toluenesulfonamide production of HongRi Pharmaceutical Co., Ltd. accepted
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
In the afternoon of May 19, HongRi pharmaceutical announced that the application for production registration of p-toluenesulfonamide (hereinafter referred to as "PTS") jointly declared by the company and its subsidiary Tianjin hongrijiandakang Pharmaceutical Technology Co., Ltd was officially accepted by the drug review center of the State Food and Drug Administration on May 15, 2014 The application scope of the third phase clinical trial of this product is central lung cancer with severe airway obstruction According to the relevant provisions of the measures for the administration of drug registration of the people's Republic of China, after the PTS production registration is accepted, the production approval can only be obtained after passing the technical review and approval procedures The results and time of interim review and approval are uncertain to some extent, and the final approval or not shall be determined after the review of relevant national departments The application for production registration of the product is accepted, which will not affect the company's recent performance.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
